Differential antagonism of the rate-decreasing effects of κ-opioid receptor agonists by naltrexone and norbinaltorphimine

European Journal of Pharmacology

Volumn 377, Issue 1, 1999, Pages 21-28

  Powell, Kelly R ^a   Holtzman, Stephen G ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Opioid receptor; Fixed interval; Naltrexone; Nor binaltorphimine; Squirrel monkey

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; BREMAZOCINE; ENADOLINE; ETHYLKETAZOCINE; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZO[B]THIOPHENE 4 ACETAMIDE; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; NALORPHINE; NALTREXONE; NORBINALTORPHIMINE; RECEPTOR SUBTYPE; SPIRADOLINE;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG POTENCY; INTRAMUSCULAR DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; SQUIRREL MONKEY; STATISTICAL ANALYSIS;

3,4-DICHLORO-N-METHYL-N-(2-(1-PYRROLIDINYL)-CYCLOHEXYL)-BENZENEACETAMIDE, (TRANS)-ISOMER; ANALGESICS; ANIMALS; BEHAVIOR, ANIMAL; BENZENEACETAMIDES; BENZOFURANS; BENZOMORPHANS; CONDITIONING, OPERANT; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHYLKETOCYCLAZOCINE; NALORPHINE; NALTREXONE; NARCOTIC ANTAGONISTS; PYRROLES; PYRROLIDINES; RECEPTORS, OPIOID, KAPPA; REINFORCEMENT SCHEDULE; SAIMIRI; THIOPHENES;

EID: 0033025167     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00394-5     Document Type: Article

References (37)

1. Bergman J., Warren P.H. Effects of kappa opioids on schedule-controlled behavior of squirrel monkeys. J. Pharmacol. Exp. Ther. 248:1989;1102-1108.
2. 3H ]-CI-977: a highly selective ligand for the k-opioid receptor in both guinea-pig and rat forebrain Mol. Pharmacol. 1:1990;23-29.
3. Broadbear J.H., Negus S.S., Butelman E.R., de Costa B.R., Woods J.H. Differential effects of systemically administered nor-binaltorphimine (nor-BNI) on k-opioid agonists in the mouse writhing assay. Psychopharmacology. 115:1994;311-319.
4. Butelman E.R., Negus S.S., AI Y., de Costam B.R., Woodsm J.H. Kappa opioid antagonist effects of systemically administered nor-binaltorphimine in a thermal antiociception assay in rhesus monkeys. J. Pharmacol. Exp. Ther. 267:1993;1269-1276.
5. 3 subtype. J. Pharmacol. Exp. Ther. 251:1989;461-468.
6. Craft R.M., Dykstra L.A. Agonist and antagonist activity of kappa opioids in the squirrel monkey: I. Antinociception and urine output. J. Pharmacol. Exp. Ther. 260:1992;327-333.
7. De Costa B.R., Band L., Rothman R.B., Jacobson A.E., Bykov V., Pert A., Rice K.C. Synthesis of an affinity ligand ('UPHIT') for in vivo acylation of the κ-opioid receptor. FEBS Lett. 249:1989;178-182.
8. Dykstra L.A., Gmerek D.E., Winger G., Woods J.H. Kappa opioids in rhesus monkeys: II. Analysis of the antagonistic actions of quadazocine and β-funaltrexamine. J. Pharmacol. Exp. Ther. 242:1987;421-427.
9. France C.P., Medzihradsky F., Woodsm J.H. Comparison of kappa opioids in rhesus monkeys: behavioral effects and receptor binding affinities. J. Pharmacol. Exp. Ther. 268:1994;47-58.
10. Gistrak M.A., Paul D., Hahn E.F., Pasternak G.W. Pharmacological actions of a novel mixed opiate agonist/antagonist: naloxone benzoylhydrazone. J. Pharmacol. Exp. Ther. 251:1989;469-476.
11. Horan P.J., Porreca F. Lack of cross-tolerance between U69,593 and bremazocine suggests K-opioid receptor multiplicity in mice. Eur. J. Pharmacol. 239:1993;93-98.
12. Horan P.J., de Costa B.R., Rice K.C., Porreca F. Differential antagonism of U69,593- and bremazocine-induced antinociception by (-)-UPHIT: evidence of kappa opioid receptor multiplicity in mice. J. Pharmacol. Exp. Ther. 257:1991;1154-1161.
13. Horan P.J., de Costa B.R., Rice K.C., Haaseth R.C., Hruby V.J., Porreca F. Differential antagonism of bremazocine- and U69,593-induced antinociception by quadazocine: further functional evidence of opioid K receptor multiplicity in the mouse. J. Pharmacol. Exp. Ther. 266:1993;926-933.
14. Iyengar S., Kim H.S., Wood P.L. Effects of kappa opiate agonists on neurochemical and neuroendocrine indices: evidence for kappa receptor subtypes. Life Sci. 39:1986;637-644.
15. Jewett D.C., Woods J.H. Nor-binaltorphimine: an ultra-long acting kappa-opioid antagonist in pigeons. Behav. Pharmacol. 6:1995;815-820.
16. Jones D.N.C., Holtzman S.G. Behavioral effects of systemically administered mu and kappa opioid agonists in the squirrel monkey: peptides versus alkaloids. Pharmacol. Biochem. Behav. 47:1994;421-426.
17. 2 analysis in rhesus monkeys. J. Pharmacol. Exp. Ther. 285:1998;518-526.
18. 3H ]U-69,593, a highly selective ligand for the opioid κ receptor Eur. J. Pharmacol. 109:1985;281-284.
19. Mattox A.J., Picker M.J., Dykstra L.A. Pharmacological analysis of the rate-decreasing effects of mu and kappa opioids in pigeons. Psychopharmacology. 113:1994;457-462.
20. Negus S.S., Burke T.F., Medzihradsky F., Woods J.H. Effects of opioid agonists selective for mu, kappa and delta opioid receptors on schedule-controlled responding in rhesus monkeys: antagonism by quadazocine. J. Pharmacol. Exp. Ther. 267:1993;896-903.
21. 3H ]ethylketocyclazocine Life Sci. 42:1988;2403-2412.
22. 3H ]U-69,593 binding sites in rat brain: evidence for κ opioid receptor subtypes Eur. J. Pharmacol. 154:1988;27-34.
23. Nock B., Giordano A.L., Cicero T.J., O'Connor L.H. Affinity of drugs and peptides for U-69,593-sensitive and insensitive kappa opiate binding sites: the U-69,593-insensitive site appears to the beta endorphin-specific epsilon receptor. J. Pharmacol. Exp. Ther. 254:1990;412-419.
24. Picker M.J. Discriminative stimulus and response rate-decreasing effects of kappa opioids: antagonism by naloxone. Life Sci. 54:1994;1767-1775.
25. Pitts R.C., Dykstra L.A. Antinociceptive and response rate-altering effects of kappa opioid agonists, spiradoline, enadoline and U69,593, alone and in combination with opioid antagonists in squirrel monkeys. J. Pharmacol. Exp. Ther. 271:1994;1501-1508.
26. Pitts R.C., West J.P., Morgan D., Dykstra L.A., Picker M.J. Opioids and rate of positively reinforced behavior: differential antagonism by naltrexone. Behav. Pharmacol. 7:1996;205-215.
27. Portoghese P.S., Lipkowski A.W., Takemori A.E. Binaltorphimine and nor-binaltorphimine: potent and selective k-opioid antagonists. Life Sci. 40:1987;1287-1292.
28. Romer D., Buscher H., Hill R.C., Maurer R., Petcher T.J., Welle H.B.A., Bakel H.C.C.K., Akkerman A.M. Bremazocine: a potent, long-acting opiate kappa agonist. Life Sci. 27:1980;971-978.
29. Rothman R.B., Bykov V., de Costa B.R., Jaconson A.E., Rice K.C., Brady L.S. Interaction of endogenous opioid peptides and other drugs with four kappa opioid binding sites in guinea pig brain. Peptides. 11:1990;311-331.
30. Takemori A.E., Ho B.Y., Neaseth J.S., Portoghese P.S. Nor-binaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays. J. Pharmacol. Exp. Ther. 246:1988;255-258.
31. 2 and receptor differentiation: a statistical analysis of competitive antagonism. Life Sci. 25:1979;637-654.
32. Tang A.H., Code R.A. Discriminative stimulus properties of nalorphine in the rhesus monkey. J. Pharmacol. Exp. Ther. 227:1983;563-569.
33. Tiberi M., Magnan J. Demonstration of the heterogeneity of the κ-opioid receptors in guinea-pig cerebellum using selective and nonselective drugs. Eur. J. Pharmacol. 188:1990;379-389.
34. VonVoigtlander P.F., Lewis R.A. Analgesic and mechanistic evaluation of spiradoline, a potent kappa opioid. J. Pharmacol. Exp. Ther. 246:1988;259-262.
35. VonVoigtlander P.F., Lahti R.A., Ludens J.H. U-50,488: a selective and structurally novel non-mu (kappa) opioid agonist. J. Pharmacol. Exp. Ther. 224:1983;7-12.
36. Young A.M., Stephens K.R. Antagonism of the discriminative effects of ethylketocyclazocine, cyclazocine, and nalorphine in macaques. Psychopharmacology. 84:1984;356-361.
37. 2 opioid receptors. Proc. Natl. Acad. Sci. U.S.A. 85:1988;406.